文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒特殊人群用药

是否需更改托吡酯治疗参考范围?

Was it necessary to change the therapeutic range of topiramate?
PubMed 文献 · Br J Clin Pharmacol · 2021-08-05

该研究基于挪威常规治疗药物监测数据,评估托吡酯血药浓度与临床结局的关系。分析1721份ADR样本和294份单药治疗样本,发现5-20 mg/L范围内儿童癫痫控制更佳,且ADR与血药浓度无关,结论为不建议更改治疗参考范围。

要点

  • 儿童血药浓度5-20 mg/L较<5 mg/L癫痫控制更优。
  • 无癫痫发作患者与有发作患者血药浓度无差异。
  • 不良反应报告率2.8%,与血药浓度无关。

核心结论

  • 不建议更改托吡酯的治疗参考范围。

研究设计与样本

  • 基于常规治疗药物监测申请单的回顾性研究,评估1721份谷浓度样本的浓度依赖性不良反应,并对294份单药治疗样本进行癫痫频率分析。

主要发现

  • 儿童整体队列无癫痫发作比例49% vs 成人37%,单药治疗中儿童56% vs 成人44%。
  • 儿童血药浓度5-20 mg/L vs <5 mg/L无发作比例65% vs 44%。
  • 儿童血药浓度5-10 mg/L vs <2 mg/L无发作比例63% vs 14%。
  • 无癫痫发作患者与有发作患者血药浓度无差异。
  • 2003-2005年癫痫控制较2006-2011年差;38份样本(2.8%)报告不良反应,与血药浓度无关。

临床怎么用

  • 临床解读托吡酯血药浓度时,可继续参考5-20 mg/L范围,尤其关注儿童癫痫控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The Norwegian Association for Clinical Pharmacology in their National Guidelines decreased the therapeutic range (TR) of topiramate (TPM) from 5-20 mg/L to 2-10 mg/L. The objective of this study is to ascertain which TR produces better clinical outcomes. METHODS: The data sources were request forms for routine therapeutic drug monitoring (TDM) of TPM. Concentration dependent adverse drug reactions (ADRs) were evaluated in 1721 samples taken pre-dose. Seizure frequency analysis was performed in 294 samples of monotherapy. Statistical analysis was performed using Prism 5.0, GraphPad Instatt: One-way ANOVA with Bonferroni correction for median plasma level (PL) and χ2 -test with Bonferroni correction for seizure frequency and for distribution of PL according to TR 5-20 mg/L and intervals <2, 2-5, 5-10, 10-20, >20 mg/L. RESULTS: Better seizure control was found in children both in the whole cohort (without seizure 49% vs 37% adults), as well as in monotherapy (56% vs 44%), in children with PL 5-20 mg/L vs <5 mg/L (65% vs 44%) and in children with PL 5-10 mg/L vs <2 mg/L (63 vs 14%). PL in seizure-free patients did not differ from those with seizure. Seizure control was poorer in the period 2003-2005 compared to 2006-2011. ADRs reported in 38 samples (2.8%) were not related to PL. CONCLUSIONS: Change of TR is not recommended.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Koristkova B, Grundmann M, Brozmanova H, et al. Was it necessary to change the therapeutic range of topiramate? Br J Clin Pharmacol. 2021. PMID: 34265104. doi:10.1111/bcp.14985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。